Paroxysmal kinesigenic dyskinesia (PKD) and myotonia congenita (MC) are independent disorders that share some clinical features. We aimed to investigate the sequences of PRRT2 and CLCN1 in a proband diagnosed with PKD and suspected MC. Clinical evaluation and auxiliary examinations were performed. Direct sequencing of the entire coding regions of the PRRT2 and CLCN1 genes was conducted. Haplotype analysis confirmed the relationships among the family members. The proband suffered choreoathetosis attacks triggered by sudden movements, and lower-limb weakness and stiffness that worsened in cold weather. Carbamazepine monotherapy completely controlled his choreoathetosis and signifi cantly relieved his limb weakness and stiffness. His father, when young, had similar limb stiffness, while his mother and brother were asymptomatic. Genetic analysis revealed that the proband and his father harbored a PRRT2 c.649dupC mutation, and CLCN1 c.1723C>T and c.2492A>G mutations. His brother carried only the two CLCN1 mutations. None of these mutations were identified in his mother and 150 unrelated controls. This is the first report showing the coexistence of PRRT2 and CLCN1 mutations. Our results also indicate that both the PRRT2 and CLCN1 genes need to be screened if we fail to identify PRRT2 mutations in PKD patients or CLCN1 mutations in MC patients.
INTRODUCTION
Paroxysmal kinesigenic dyskinesia (PKD) is an episodic movement disorder characterized by involuntary attacks that are usually precipitated by sudden movements. It is transmitted in an autosomal dominant pattern with high penetrance [1] . PKD is clinically heterogeneous, manifesting as any combination of choreoathetosis, ballismus, and dystonia. It typically responds well to antiepileptic drugs, among which carbamazepine and phenytoin are usually considered the drugs of choice [1, 2] . Recent studies from independent groups have shown that mutations within PRRT2 are causative for PKD [3] [4] [5] [6] . More than 50 PRRT2 mutations have been documented so far, among which c.649dupC has been shown to be a mutation hotspot [7] [8] [9] .
Myotonia congenita (MC) is a muscle disorder distinguished by impaired relaxation after voluntary contraction, and variable degrees of stiffness and hypertrophy [10] . The warm-up phenomenon is a specifi c sign of MC, for the myotonia usually worsens after prolonged rest or in cold weather but improves with repetitive movements [11] . MC can be transmitted as an autosomal dominant or recessive trait, known as Thomsen disease or
Becker disease, respectively [12] . Both forms are attributed to mutations within the CLCN1 gene, which is mapped to chromosome 7q35 and encodes the skeletal muscle chloride channel [13] . CLCN1 mutations lead to dysfunction of the chloride channel and reduction of chloride conductance, increasing membrane hyperexcitability and delaying muscle fiber relaxation [14] . So far, >150 CLCN1 mutations have been reported to cause dominant or recessive MC (see www.hgmd.cf.ac.uk). However, certain mutations have been found to cause both forms [13, 15] . Sodium-channel blockers such as carbamazepine, phenytoin, and mexiletine are available for MC, usually resulting in a favorable effect [16, 17] .
Although PKD and MC are independent disorders, they share some clinical features. For example, both present with stiffness or muscle weakness in the extremities, and these are especially pronounced on initiating an action.
Moreover, they both commence in childhood, affect more males than females [18, 19] , and respond favorably to carbamazepine or phenytoin [17] . These fi ndings can make it diffi cult to clinically distinguish PKD from MC.
In the current study, we present a Chinese patient affected with choreoathetosis attacks and muscle weakness and stiffness that were usually induced by sudden movements, and investigated the sequences of the PRRT2 and CLCN1 genes. 
PARTICIPANTS AND METHODS

Participants
Mutation Analysis
Genomic DNA was extracted from peripheral blood using the standard protocol. Since the proband was diagnosed with PKD and suspected MC, we directly sequenced the entire coding regions of the PRRT2 and CLCN1 genes.
Primers for PRRT2 were described previously [3] , and primers for CLCN1 were designed and are listed in Table   1 . Amplifi cation products were purifi ed with shrimp alkaline phosphatase and exonuclease, followed by direct DNA sequencing using an ABI 3730 Automated DNA Sequencer (Applied Biosystems, Foster City, CA). The sequences were aligned with NCBI human genome reference MIM 614386 and MIM 118425, respectively.
Haplotype Analysis
To confirm that these four family members were genetically related, we conducted haplotype analysis based on 20 single nucleotide polymorphisms (SNPs) using the Sequenom MassArray system at Fudan-Van Andel Research Institute Center (School of Life Science, Fudan University, Shanghai). Alleles were detected using matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry. Primers for 18 of the 20 SNPs were described previously [8] , and primers for the other two (rs3851760 and rs2071390) are listed in Table S1 .
RESULTS AND DISCUSSION
The 21-year-old proband had an unremarkable birth, but We made a diagnosis of PKD, performed direct sequencing of the PRRT2 gene, and identifi ed a c.649dupC
(p.R217Pfs8) mutation (Fig. S1 ). In a previous study, we had found that PKD cases with the PRRT2 mutation responded completely to 50 mg carbamazepine once daily [2] , so this dose was prescribed. His choreoathetosis completely disappeared and he did not report any sideeffects. However, he still complained of weakness and stiffness in his lower extremities when he started leg movements. We then increased the dosage of carbamazepine to 100 mg once daily, which had limited effects. However, a further increase to 100 mg twice daily controlled his limb weakness and stiffness. Clearly, the proband had an incomplete response to 50 mg carbamazepine, although he carried a PRRT2 mutation.
We then made a detailed inquiry about his attacks. The proband said that the weakness and stiffness in his lower extremities worsened in cold weather but were relieved after repetitive movements. We thereby conjectured that he might coincidently exhibit MC symptoms. No muscle hypotrophy was observed in his lower limbs. Percussion of his gastrocnemius muscle, however, showed a mild myotonia. EMG showed diffuse and abundant myotonic discharges. The nerve conduction study was normal. We (Fig. S2 ) and c.2492A>G (p.Q831R) (Fig. 1) . The c.1723C>T mutation has been reported to have recessive effects [20] , while c.2492A>G is a novel mutation. Q831 is located in the cystathionine beta-synthase 2 (CBS2) domain of CLC-1 and is highly conserved [21] (Fig. S3) . It has been suggested that mutations in the CBS domains affect the proteinprotein interactions within CLC protein subunits and between the subunits of CBS dimers [22] . The pathogenic status of the p.Q831R mutation was not investigated in this study. However, it was not found in the 150 normal individuals, arguing against its polymorphism.
His father suffered from limb stiffness between 15
and 20 years of age; this usually occurred after initiating a movement and worsened in cold weather. The father had not taken any medication because his symptoms were tolerable and disappeared after he was 20 years old.
Neither his mother nor his brother was clinically affected.
No remarkable changes in the physical and auxiliary examinations were found in his father, brother, and mother.
Evaluation of the PRRT2 and CLCN1 sequences in his family members revealed that his father harbored the same PRRT2 and CLCN1 mutations as the proband, but his brother carried only the two CLCN1 mutations. Neither the PRRT2 nor CLCN1 mutations were identified in his mother and the 150 unrelated controls. To ensure that the results of mutation screening were correct, we collected the samples again from the 4 family members, repeated the DNA sequencing, and obtained the same results.
We then performed haplotype analysis in this family and found that the proband inherited one haplotype from his mother and one from his father (Fig. 2) . His brother inherited the same haplotype from his mother and a different haplotype from his father. The biological relationships among these family members were confi rmed.
Here, we present a family carrying a PRRT2 c.649dupC mutation and two CLCN1 mutations, indicating the coexistence of PKD and MC. The proband had a predominant phenotype of choreoathetosis and additional signs of myotonia. We previously found that PRRT2 mutation carriers respond completely to 50 mg carbamazepine [2] , but the case described here did not have a complete response.
This might be partly due to the influence of the CLCN1 mutations on the PKD phenotype, resulting in a less favorable response to carbamazepine.
The PRRT2 c.649dupC mutation was also identifi ed in the patient's father. However, the father did not appear to have PKD symptoms, suggesting incomplete penetrance.
In addition, the proband's brother carried two CLCN1
mutations, but he did not present MC symptoms either. This implied that the CLCN1 mutations were not expressed, or the signs were too mild to be noticed in the brother. An Additional experiments to investigate the genetic modifi ers in these individuals are needed.
Both the proband and his brother inherited the two heterozygous CLCN1 mutations from their father, indicating that these mutations are located in the same chromatid.
In addition, the proband and his father harbored a PRRT2 mutation. Actually, the coincidence of a CLCN1 mutation with other mutations such as CNBP expansion is not uncommon in the literature [23] [24] [25] . Suominen et al. reported that 5% of myotonic dystrophy type 2 (DM2) patients, and 1% of DM1 patients in Germany co-segregate with the CLCN1 p.R894X mutation [23] . In addition, they found that 3%
of Finnish DM2 patients are carriers of the CLCN1 p.R894X mutation, and 2% carry the CLCN1 p.F413C mutation [23] .
In a large Norwegian DM2 family, Sun et al. found that 6 patients carried CNBP expansion and the CLCN1 p.F413C mutation, while 7 others harbored only CNBP expansion [24] .
The 6 affected carriers showed more severe symptoms and EMG myotonia. Thus, it seems that CLCN1 mutation modifies the phenotypic effects of CNBP expansion and thereby exaggerates the severity of myotonia.
The pathological mechanism underlying PKD is still poorly understood. But it responds favorably to antiepileptic drugs, especially carbamazepine and phenytoin, which regulate ion channels [1, 2] . Hence, ion channel abnormality might be one of the mechanisms underlying PKD [26] . Yeast two-hybrid studies suggested that PRRT2 protein interacts with synaptosomal associated protein 25 (SNAP25) [27] , a presynaptic membrane protein engaged in synaptic vesicle handling. SNAP25 plays a crucial role in the regulation of intracellular Ca 2+ concentration and neuronal exocytosis [28] . It is thus possible that mutation of PRRT2 impairs its interaction with SNAP25, infl uencing Ca 2+ dynamics and neurotransmitter release. However, solid evidence is still lacking.
To the best of our knowledge, this is the first report on the coexistence of PRRT2 and CLCN1 mutations in the same family. Since PKD and MC share some clinical features, cautious consideration is needed in diagnosis. We therefore suggest that researchers and clinicians screen for both genes if they fail to identify PRRT2 mutations in PKD patients or CLCN1 mutations in MC patients.
SUPPLEMENTAL DATA
Supplemental data include one table and three fi gures and can be found online at http://www.neurosci.cn/epData.asp?id=212.
